RT Journal Article
SR Electronic
T1 Distinct single cell gene expression in peripheral blood monocytes correlates with treatment response groups defined by type I interferon in rheumatoid arthritis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19011460
DO 10.1101/19011460
A1 Theresa L. Wampler Muskardin
A1 Wei Fan
A1 Zhongbo Jin
A1 Mark A. Jensen
A1 Jessica M. Dorschner
A1 Yogita Ghodke-Puranik
A1 Betty Dicke
A1 Danielle Vsetecka
A1 Kerry Wright
A1 Thomas Mason
A1 Scott Persellin
A1 Clement J. Michet
A1 John M. Davis
A1 Eric Matteson
A1 Timothy B. Niewold
YR 2019
UL http://medrxiv.org/content/early/2019/11/12/19011460.abstract
AB Objective Previously, we have shown that the ratio of IFNβ/α activity can predict response to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). In this study, our objective was to better understand the impact of this type I IFN ratio in monocytes from RA patients.Methods We compared single cell gene expression in purified classical (CL) and non-classical (NC) monocytes from RA patients. Patients with high vs. low serum IFNβ/α ratio were compared to each other, as determined by functional type I IFN assay.Results We found large differences in monocyte gene expression between patients with different IFNβ/α ratios, which was apparent in principal component analysis. Cluster analysis also documented strong differences between these response groups. In CL monocytes, decreased expression of JAK1 and IFI27 were strongly associated with the non-response low IFNβ/α ratio. In NC monocytes, increased expression of HLADRB1, TNFA, PDL1, TGFB, and others were associated with the non-response IFN ratio. Interestingly, JAK1 expression was absent in all monocytes from some patients. This pattern was strongly associated with the non-response type I IFN ratio, suggesting a major biological difference between JAK1 expressors and non-expressors.Conclusions Differences in the ratio of IFNβ/α are associated with major changes in gene expression in RA patient monocytes, suggesting differential IFN pathway activation in RA patients who are either more or less likely to respond to TNFi. This work could suggest mechanisms for TNFi non-response, as well as potential therapeutic strategies for those patients who would not to respond to TNFi.Competing Interest StatementDr. Niewold holds research grants from EMD Serono and Microdrop, Inc. which are not related to this study. Drs. Niewold and Wampler Muskardin have filed a patent on biomarker testing for the prediction of drug response in rheumatoid arthritis.Funding StatementTWM: Arthritis National Research Foundation Arthritis Research Award; NYU Colton Center for Autoimmunity; NYU Department of Medicine Sapperstein Scholar Award; NYU CTSI Scholar Award; Central Society for Clinical and Translational Medicine Career Development Award; Mayo Clinic Career Development Award in Rheumatoid Arthritis Research; TBN: NIH (AR060861, AR057781, AR065964, DK107984), Rheumatology Research Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in this manuscript is available upon reasonable request.